Aprea Therapeutics Inc

aprea.com

What Do They Do?

Develops targeted small-molecule cancer therapies for patients whose tumors have specific genetic markers.

Do Revenues Turn Into Profits?

No. It lost $12.6M in .

Operating income,

−4630% of revenue

▼ −8% (Loss) vs (−$14.3M, −953%)

Net income,

−4409% of revenue

▼ −3% (Loss) vs (−$13M, −862%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Net income: ▲ +11% (Loss); vs −$3.2M in Q2 FY2025

Jul 23, 2026 Nasdaq gave Aprea more time to meet its minimum bid price The added compliance period runs through January 19, 2027; Nasdaq may delist the stock if the company does not meet the requirement.

Lead program priority The older report describes the ATR inhibitor as the lead program and the cell-cycle inhibitor as preclinical; the latest report foregrounds the cell-cycle inhibitor and presents the ATR inhibitor as another clinical program.

Who Do They Compete With?

Competes with Zentalis Pharmaceuticals, Debiopharm, IMPACT Therapeutics, Schrodinger, Acrivon Therapeutics, Artios Pharma, AstraZeneca, Merck, and Xeno Therapeutics

Comments